{"title":"Shire Bolsters its Haematology Business with US$325 M FerroKin BioSciences Acquisition","authors":"Heather Cartwright","doi":"10.3833/PDR.V2012I3.1702","DOIUrl":null,"url":null,"abstract":"Shire has moved to strengthen its haematology franchise by agreeing to acquire FerroKin BioSciences for up to US$325 M. With the acquisition, Shire will gain FerroKin’s iron chelator FBS0701, which is in Phase II development for the treatment of iron overload due to chronic blood transfusions. Shire will pay US$100 M upfront in cash and up to US$225 M in potential clinical development, regulatory and commercial milestones related to the drug, which could be launched as early as 2016.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"6 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2012-03-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/PDR.V2012I3.1702","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0
Abstract
Shire has moved to strengthen its haematology franchise by agreeing to acquire FerroKin BioSciences for up to US$325 M. With the acquisition, Shire will gain FerroKin’s iron chelator FBS0701, which is in Phase II development for the treatment of iron overload due to chronic blood transfusions. Shire will pay US$100 M upfront in cash and up to US$225 M in potential clinical development, regulatory and commercial milestones related to the drug, which could be launched as early as 2016.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
